<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342949</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(I)-20180113</org_study_id>
    <nct_id>NCT04342949</nct_id>
  </id_info>
  <brief_title>The Auxiliary Effects of Fucoidan for Locally Advanced Rectal Cancer Patients</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Parallel Study to Investigate the Auxiliary Effects of Fucoidan in Patients With Locally Advanced Rectal Cancer Who Receive Combined Radio-chemotherapy Before Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, parallel study. The main goal is to
      investigate the auxiliary effects of Fucoidan for the patients with locally advanced rectal
      cancer who receive neoadjuvant CCRT before surgery. The quality of life is our primary
      endpoint for this study. The study is an observational study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>auxiliary effects of Fucoidan</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the quality of life after unblind by 4th edit of FACT-C</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>To Observe Whether the Fucoidan Can Improve the Quality of Life of the Such Patients Receiving the Neoadjuvant CCRT</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>quality of life</intervention_name>
    <description>To observe the difference of quality of life</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        we enrolled the patients with locally advanced rectal cancers and received neoadjuvant CCRT
        (concurrent radiochemotherapy) before.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age was more/equal to 20 year-old and less/equal to 80 year-old

          2. Diagnosed as locally advanced rectal cancers by pathological biopsy and image study.

          3. ECOG performance status within 0 to 2 points

          4. Excepted life remaining at least 4 months

          5. Females with fertility are willing to use effective contraception during the period of
             study

          6. Willing to follow the test procedures and tracking procedures

          7. sign the inform consent form

        Exclusion Criteria:

        1.Suffering from other primary malignant tumors 2.Females who are pregnant, planning to
        become pregnant, or breastfeeding 3.Participate in other interventional clinical trial
        within the first 30 days 4.Suffering from major mental illness such as mental retardation
        and mental disorders 5.Unable to understand and answer research questions (oral or written)
        6.Abnormal laboratory data within 14 days before joining the study 7.Evidence that subject
        has a severe or uncontrolled disease

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaw-Yuan Wang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsiang-Lin Tsai, Ph.D</last_name>
    <phone>+88673121101</phone>
    <phone_ext>5553</phone_ext>
    <email>chunpin870132@yahoo.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaw-Yuan Wang, Ph.D</last_name>
    <phone>+88673121101</phone>
    <phone_ext>5557</phone_ext>
    <email>cy614112@ms14.hinet.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chung-Ho Memorial Hospital, Kaohsiung Medical University:</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaw-Yuan Wang, PhD</last_name>
      <email>cy614112@ms14.hinet.net</email>
    </contact>
    <contact_backup>
      <last_name>Hsiang-Lin Tsai, PH.D</last_name>
      <email>chunpin870132@yshaoo.com.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Jaw-Yuan Wang, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsiang-Lin Tsai, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University Chung-Ho Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Jaw-Yuan Wang, MD, PhD</investigator_full_name>
    <investigator_title>Vice Superintendent, Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

